Uønskede hændelser eller laboratorie- abnormaliteter medførte, at 5% af patienterne skulle have seponeret Pegasys- behandlingen, mens mindre end 1% af patienterne skulle have seponeret lamivudin- behandlingen grundet disse årsager.
Adverse events or laboratory abnormalities led to 5% of patients withdrawing from Pegasys treatment, while less than 1% of patients withdrew from lamivudine treatment for these reasons.